Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 11, 2012, Pages 805-813

  Buldak, Lukasz ^a   Dulawa Buldak, Anna ^a   Labuzek, Krzysztof ^a   Okopien, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipokines; Atorvastatin; Fenofibrate; Insulin resistance; Proinflammatory cytokines

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CYTOKINE; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COUNSELING; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADIPONECTIN; ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; FENOFIBRATE; GLUCOSE METABOLISM DISORDERS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE V; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LEPTIN; LIPIDS; MALE; MIDDLE AGED; POLAND; PYRROLES; RESISTIN; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867908899     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201735     Document Type: Article

References (36)

1. Piechota G, Małkiewicz J, Karwat ID. (Obesity as a cause and result of disability). Przegl Epidemiol. 2005; 59: 155-161. PubMed
2. Brunner D, Altman S, Loebl K, Schwartz S, Levin S. Serum cholesterol and triglycerides in patients suffering from ischemic heart disease and in healthy subjects. Atherosclerosis. 1977; 28: 197-204. doi:10.1016/0021-9150(77)90157-5 PubMed (Pubitemid 8213765)
3. Achike FI, To NH, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. Clin Exp Pharmacol Physiol. 2011; 38: 1-10. doi:10.1111/j.1440-1681.2010.05460.x PubMed
4. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOTLLA). Diabetes Care. 2005; 28: 1151-1157. doi:10.2337/diacare.28.5.1151 PubMed (Pubitemid 40616627)
5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364: 685-696. doi:10.1016/S0140-6736(04)16895-5 PubMed (Pubitemid 39140624)
6. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992; 85: 37-45. doi:10.1161/01.CIR.85.1.37 PubMed
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497. doi:10.1001/jama.285.19.2486 PubMed
8. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007; 186: 461-465. PubMed (Pubitemid 46806823)
9. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006; 29: 1220-1226. doi:10.2337/dc05-2465 PubMed (Pubitemid 44125913)
10. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359: 2195-2207. doi:10.1056/NEJMoa0807646 PubMed
11. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002; 162: 2597-2604. doi:10.1001/archinte.162.22.2597 PubMed (Pubitemid 35453499)
12. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wójcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest. 2000; 30: 871-878. doi:10.1046/j.1365-2362.2000.00734.x PubMed
13. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey WT. The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab. 1997; 82: 1293-1300. doi:10.1210/jc.82.4.1293 PubMed (Pubitemid 27166679)
14. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003; 149: 331-335. doi:10.1530/eje.0.1490331 PubMed (Pubitemid 37304704)
15. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med. 2002; 8: 1288-1295. doi:10.1038/nm788 PubMed (Pubitemid 35373562)
16. Jovinge S, Hamsten A, Tornvall P, Proudler A, Båvenholm P, Ericsson CG, Godsland I, de Faire U, Nilsson J. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism. 1998; 47: 113-118. doi:10.1016/S0026- 0495(98)90203-7 PubMed (Pubitemid 28086243)
17. Krysiak R, Labuzek K, Okopieñ B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep. 2009; 61: 1134-1145. PubMed
18. Jeong S, Yoon M. Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice. Exp Mol Med. 2009; 41: 397-405. doi:10.3858/emm.2009.41.6.045 PubMed
19. Okopieñ B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab. 2006; 91: 1770-1778. doi:10.1210/jc.2005-1615 PubMed
20. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005; 54: 3358-3370. doi:10.2337/diabetes.54.12.3358 PubMed (Pubitemid 43334324)
21. Whitelaw DC, Smith JM, Nattrass M. Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. Diabetes Obes Metab. 2002; 4: 187-194. doi:10.1046/j.1463-1326.2002.00199.x PubMed (Pubitemid 34567675)
22. Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia. Endocr J. 2007; 54: 431-435. doi:10.1507/endocrj.K06-172 PubMed (Pubitemid 47105431)
23. Gualillo O, González-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med. 2007; 17: 275-283. doi:10.1016/j.tcm.2007. 09.005 PubMed (Pubitemid 350087698)
24. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006; 86: 515-581. doi:10.1152/physrev.00024. 2005 PubMed
25. Metais C, Forcheron F, Abdallah P, Basset A, Del Carmine P, Bricca G, Beylot M. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin. Metabolism. 2008; 57: 946-953. doi:10.1016/j.metabol.2008.02.010 PubMed (Pubitemid 351814687)
26. Damci T, Tatliagac S, Osar Z, Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med. 2003; 14: 357-360. doi:10.1016/S0953-6205(03)90001-X PubMed (Pubitemid 40090259)
27. Ogawa S, Takeuchi K, Sugimura K, Fukuda M, Lee R, Ito S, Sato T. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism. 2000; 49: 331-334. doi:10.1016/S0026-0495(00)90176-8 PubMed (Pubitemid 30146563)
28. Hung YJ, Pei D, Wu DA, Kuo SW, Fuh MM, Jeng C. Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to highdensity lipoprotein cholesterol. J Formos Med Assoc. 1999; 98: 104-110. PubMed (Pubitemid 29122790)
29. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol. 2007; 27: 635-641. doi:10.1161/01.ATV.0000256469.06782.d5 PubMed
30. Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol. 2006; 61: 263-269. doi:10.2143/AC.61.3.2014826 PubMed
31. Chu CH, Lee JK, Lam HC, Lu CC, Sun CC, Wang MC, Chuang MJ, Wei MC. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. J Endocrinol Invest. 2008; 31: 42-47. PubMed (Pubitemid 351403827)
32. Martínez-García MA, Luque-Ramírez M, San- Millán JL, Escobar-Morreale HF. Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. Diabetes Care. 2009; 32: 1525-1530. doi:10.2337/dc09-0420 PubMed
33. Sebestjen M, Keber I, Zegura B, Simcic S, Bozic M, Fressart MM, Stegnar M. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost. 2004; 92: 1129-1135. PubMed (Pubitemid 39545539)
34. Krysiak R, Okopien B. The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report. Atherosclerosis. 2010; 213: 325-328. doi:10.1016/j.atherosclerosis. 2010.07.016 PubMed
35. Chudek J, Wiecek A. Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep. 2006; 58 (Suppl): 81-88. PubMed
36. Gokulakrishnan K, Anjana RM, Indulekha K, Anuradha S, Mohan V. Association of hypoadiponectinemia with non-alcoholic fatty liver disease in urban south Indians - (CURES - 81). Indian J Med Res. 2010; 132: 271-277. PubMed